NextGen Healthcare Zukünftiges Wachstum

Future Kriterienprüfungen 3/6

NextGen Healthcare wird ein Gewinn- und Umsatzwachstum von 41.8% bzw. 6.7% pro Jahr prognostiziert, während der Gewinn pro Aktie um 42.6% pro Jahr wachsen soll.

Wichtige Informationen

41.8%

Wachstumsrate der Gewinne

42.6%

EPS-Wachstumsrate

Healthcare Services Gewinnwachstum30.7%
Wachstumsrate der Einnahmen6.7%
Zukünftige Eigenkapitalrenditen/a
Analystenabdeckung

Good

Zuletzt aktualisiert25 Oct 2023

Jüngste Aktualisierungen zum künftigen Wachstum

NextGen Healthcare, Inc. Just Recorded A 16% EPS Beat: Here's What Analysts Are Forecasting Next

Jul 27
NextGen Healthcare, Inc. Just Recorded A 16% EPS Beat: Here's What Analysts Are Forecasting Next

Recent updates

Is There An Opportunity With NextGen Healthcare, Inc.'s (NASDAQ:NXGN) 49% Undervaluation?

Aug 24
Is There An Opportunity With NextGen Healthcare, Inc.'s (NASDAQ:NXGN) 49% Undervaluation?

NextGen Healthcare, Inc. Just Recorded A 16% EPS Beat: Here's What Analysts Are Forecasting Next

Jul 27
NextGen Healthcare, Inc. Just Recorded A 16% EPS Beat: Here's What Analysts Are Forecasting Next

Investors Will Want NextGen Healthcare's (NASDAQ:NXGN) Growth In ROCE To Persist

Jul 13
Investors Will Want NextGen Healthcare's (NASDAQ:NXGN) Growth In ROCE To Persist

We Think NextGen Healthcare (NASDAQ:NXGN) Can Manage Its Debt With Ease

Jun 08
We Think NextGen Healthcare (NASDAQ:NXGN) Can Manage Its Debt With Ease

Calculating The Fair Value Of NextGen Healthcare, Inc. (NASDAQ:NXGN)

May 19
Calculating The Fair Value Of NextGen Healthcare, Inc. (NASDAQ:NXGN)

What Does NextGen Healthcare, Inc.'s (NASDAQ:NXGN) Share Price Indicate?

Mar 14
What Does NextGen Healthcare, Inc.'s (NASDAQ:NXGN) Share Price Indicate?

We Think NextGen Healthcare (NASDAQ:NXGN) Can Manage Its Debt With Ease

Feb 27
We Think NextGen Healthcare (NASDAQ:NXGN) Can Manage Its Debt With Ease

Is NextGen Healthcare, Inc. (NASDAQ:NXGN) Expensive For A Reason? A Look At Its Intrinsic Value

Dec 08
Is NextGen Healthcare, Inc. (NASDAQ:NXGN) Expensive For A Reason? A Look At Its Intrinsic Value

These Return Metrics Don't Make NextGen Healthcare (NASDAQ:NXGN) Look Too Strong

Oct 27
These Return Metrics Don't Make NextGen Healthcare (NASDAQ:NXGN) Look Too Strong

At US$17.85, Is It Time To Put NextGen Healthcare, Inc. (NASDAQ:NXGN) On Your Watch List?

Sep 30
At US$17.85, Is It Time To Put NextGen Healthcare, Inc. (NASDAQ:NXGN) On Your Watch List?

NextGen Enterprise solution to be used by NY-based health center

Sep 28

NextGen Healthcare, Inc.'s (NASDAQ:NXGN) Intrinsic Value Is Potentially 75% Above Its Share Price

Sep 07
NextGen Healthcare, Inc.'s (NASDAQ:NXGN) Intrinsic Value Is Potentially 75% Above Its Share Price

NextGen Healthcare (NASDAQ:NXGN) Is Finding It Tricky To Allocate Its Capital

Jul 29
NextGen Healthcare (NASDAQ:NXGN) Is Finding It Tricky To Allocate Its Capital

NextGen Healthcare Non-GAAP EPS of $0.16 in-line, revenue of $153.3M in-line, 2023 revenue outlook below estimates

Jul 26

Is It Too Late To Consider Buying NextGen Healthcare, Inc. (NASDAQ:NXGN)?

May 17
Is It Too Late To Consider Buying NextGen Healthcare, Inc. (NASDAQ:NXGN)?

NextGen At A Crossroads

Oct 13

Is There An Opportunity With NextGen Healthcare, Inc.'s (NASDAQ:NXGN) 44% Undervaluation?

Jun 29
Is There An Opportunity With NextGen Healthcare, Inc.'s (NASDAQ:NXGN) 44% Undervaluation?

Gewinn- und Umsatzwachstumsprognosen

NasdaqGS:NXGN - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
DatumUmsatzGewinneFreier CashflowBargeld aus operativen TätigkeitenDurchschn. Anz. Analysten
3/31/202682485851313
3/31/202577062731018
3/31/20247193912638
9/30/2023695-6-43-8N/A
6/30/20236782440N/A
3/31/2023653-3644N/A
12/31/2022626231653N/A
9/30/2022614203267N/A
6/30/202260401849N/A
3/31/202259622554N/A
12/31/202158913159N/A
9/30/2021581-44271N/A
6/30/2021572135381N/A
3/31/2021557107099N/A
12/31/202054967297N/A
9/30/2020545106893N/A
6/30/202053956286N/A
3/31/202054075986N/A
12/31/2019539165382N/A
9/30/2019532164976N/A
6/30/2019528233764N/A
3/31/2019529242550N/A
12/31/2018530102652N/A
9/30/201853162451N/A
6/30/201853313563N/A
3/31/201853124574N/A
12/31/2017528185784N/A
9/30/2017524276792N/A
6/30/201751823N/A111N/A
3/31/201751018N/A110N/A
12/31/2016505-2N/A95N/A
9/30/2016494-6N/A83N/A
6/30/2016493-1N/A50N/A
3/31/20164926N/A41N/A
12/31/201549333N/A51N/A
9/30/201549932N/A54N/A
6/30/201549429N/A68N/A
3/31/201549027N/A83N/A
12/31/201447722N/A91N/A
9/30/20144623N/A103N/A
6/30/20144538N/A91N/A
3/31/201444516N/A104N/A
12/31/20134416N/A95N/A
9/30/201344635N/A82N/A
6/30/201345140N/A80N/A
3/31/201346043N/A68N/A
12/31/201245862N/A61N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: NXGN wird in den nächsten 3 Jahren voraussichtlich rentabel werden, was als schnelleres Wachstum als die Sparquote angesehen wird (2.2%).

Ertrag vs. Markt: NXGN wird in den nächsten 3 Jahren voraussichtlich rentabel werden, was als überdurchschnittliches Marktwachstum angesehen wird.

Hohe Wachstumserträge: NXGN wird voraussichtlich in den nächsten 3 Jahren rentabel werden.

Einnahmen vs. Markt: NXGNDie Einnahmen des Unternehmens (6.7% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt US (9% pro Jahr).

Hohe Wachstumseinnahmen: NXGNDie Einnahmen des Unternehmens (6.7% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.


Wachstumsprognosen für den Gewinn je Aktie


Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von NXGN in 3 Jahren voraussichtlich hoch sein wird


Wachstumsunternehmen entdecken